Diabetic Nephropathy and Proton Pump Inhibitors - Pilot Case-Control Study

Area of Science:

• Nephrology
• Gastroenterology
• Endocrinology

Background:

• Proton pump inhibitors (PPIs) are widely used and generally considered safe.
• Emerging evidence suggests a potential link between long-term PPI use and chronic kidney disease.
• Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM).

Purpose of the Study:

• To investigate the association between proton pump inhibitor (PPI) use and diabetic nephropathy (DN) in patients with type 2 diabetes mellitus (T2DM).

Main Methods:

• A case-control study was conducted over two years (April 2017-March 2019).
• Cases comprised T2DM patients with DN, while controls were age- and sex-matched T2DM patients without DN.
• 200 participants (100 cases, 100 controls) were recruited.

Main Results:

• 62% of cases and 42% of controls reported PPI use (P=0.005).
• Pantoprazole was the most frequently used PPI.
• Increased duration of PPI use was significantly associated with DN (adjusted OR: 1.171, P=0.023).

Conclusions:

• A significant association exists between PPI use and DN in T2DM patients.
• The benefits of PPIs in T2DM, such as glycemic control, necessitate a risk-benefit evaluation for long-term use.
• Further research is warranted to understand this association and guide clinical practice.